New treatment study for grade II acute GVHD after transplant
Treatments studied
Part of Immune system & allergy clinical trials.
This study tests a new first-line therapy for patients who develop grade II acute graft-versus-host disease (GVHD) after their first stem cell transplant. It aims to find better ways to treat this complication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer or blood disease and had a stem cell transplant from a donor.
- You have been diagnosed with grade II acute GVHD (intermediate or high risk) within 100 days after transplant.
- You have not had any prior treatment for acute GVHD.
- You are not pregnant or breastfeeding.
- Your kidneys, liver, heart, and lungs are working well enough to safely take part.
- You have not used a Janus kinase inhibitor since your transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new medications for people who develop severe acute graft-versus-host disease (aGVHD) within 100 days after their first stem cell transplant. The goal is to find safer, more effective ways to control aGVHD and improve recovery.
This trial tests a drug called ruxolitinib for treating acute graft-versus-host disease (aGVHD), a common complication after a stem cell transplant. It may help control the immune reaction without using high doses of steroids.
This study tests an experimental medicine called gecacitinib for people who have graft-versus-host disease (GVHD) after a stem cell transplant and whose GVHD did not improve with standard second-line treatment (ruxolitinib). The goal is to see if this new treatment can help control GVHD symptoms.
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
This trial tests whether the drug ruxolitinib, given based on a blood test that predicts risk, can prevent chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It may help people who have a higher risk of developing this complication.
This trial compares two treatments, ruxolitinib and prednisone, as the first therapy for chronic graft-versus-host disease (cGVHD), a condition where donor cells attack your body after a stem cell transplant. The goal is to see which medicine works better and has fewer side effects.
Hear when a new GVHD,Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.